logo

For the Inventor, By the Inventor

Toyonaka, Japan

Ryuji M Marumoto

This inventor holds 11 USPTO granted patents. Top assignee: Takeda Chemical Industries, Inc.. Active years: 1976-1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryuji M Marumoto. Retrieved from https://idiyas.com/inventor/ryuji-m-marumoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 98(Granted Patents)


Location History:

  • Osaka, JA (1976)
  • Toyonaka, JP (1978)
  • Minoo, JP (1980 - 1981)
  • Osaka, JP (1981)
  • Okuikeminami, JP (1990)
  • Ashiya, JP (1982 - 1992)

Company Filing History:

goldMedal11 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents

Years Active: 1976-1992

Loading Chart...
11 patents (USPTO):Explore Patents
1. 5175268 - DNA encoding recombinant human lymphotoxin (1992-12-29),
2. 4968674 - Antiviral carbocyclic purine nucleosides (1990-11-06),
3. 4935352 - Expression vector for animal cell line and use thereof (1990-06-19),
4. 4341769 - 2,6-Diaminonebularines, their production and use (1982-07-27),
5. 4293690 - Production of 2,6-diaminonebularines (1981-10-06),
6. 4258033 - 2,6-Diaminonebularines (1981-03-24),
7. 4255565 - Production of 2,6-diaminonebularines (1981-03-10),
8. 4225591 - 2,6-Diaminonebularines (1980-09-30),
9. 4202975 - Isoxazolo[3,4-d]pyrimidines (1980-05-13),
10. 4129654 - Isoxazolo[3,4-d]pyrimidines useful as antiinflammatory-analgesic agents (1978-12-12),
11. 3936439 - 2,6-Diaminonebularine derivatives (1976-02-03),

Title: Ryuji M Marumoto: Innovator in Antiviral Research

Introduction

Ryuji M Marumoto is a prominent inventor based in Toyonaka, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antiviral agents. With a total of 11 patents to his name, Marumoto's work has had a substantial impact on medical research and treatment options.

Latest Patents

Among his latest patents, Marumoto has developed a DNA encoding recombinant human lymphotoxin. This lymphotoxin mutein is genetically altered and features a specific amino acid sequence where 10 to 21 amino acids of lymphotoxin are deleted from the N-terminus. The modified protein has Pro or Phe at the N-terminus, enhancing its potential therapeutic applications. Additionally, he has patented antiviral carbocyclic purine nucleosides, which are compounds useful as antiviral agents. These compounds include a hydroxyl group that may be protected and a purine base that may also be protected, showcasing his innovative approach to combating viral infections.

Career Highlights

Ryuji M Marumoto is affiliated with Takeda Chemical Industries, Inc., a leading company in the pharmaceutical sector. His work at Takeda has allowed him to collaborate with other experts in the field, further advancing research in antiviral therapies.

Collaborations

Some of Marumoto's notable coworkers include Yoshiyasu Furukawa and Masao Tanabe. Their collaborative efforts have contributed to the success of various projects and patents, enhancing the overall impact of their research.

Conclusion

Ryuji M Marumoto's innovative contributions to biotechnology and antiviral research have established him as a key figure in his field. His patents reflect a commitment to advancing medical science and improving treatment options for viral infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…